DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 164 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is 0.21 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $23,595,000 | -20.9% | 1,500,000 | -18.9% | 0.12% | -32.2% |
| Q4 2023 | $29,840,500 | +34.1% | 1,850,000 | +5.7% | 0.18% | +10.9% |
| Q3 2023 | $22,260,000 | -9.7% | 1,750,000 | 0.0% | 0.16% | +33.1% |
| Q2 2023 | $24,640,000 | -8.9% | 1,750,000 | 0.0% | 0.12% | -29.5% |
| Q1 2023 | $27,037,500 | +32.0% | 1,750,000 | +40.0% | 0.18% | +8.0% |
| Q4 2022 | $20,487,500 | -11.4% | 1,250,000 | 0.0% | 0.16% | +10.9% |
| Q3 2022 | $23,125,000 | +17.2% | 1,250,000 | -16.7% | 0.15% | +26.7% |
| Q2 2022 | $19,725,000 | +1138.2% | 1,500,000 | +819.7% | 0.12% | +1833.3% |
| Q4 2021 | $1,593,000 | -91.7% | 163,100 | -71.0% | 0.01% | -92.3% |
| Q3 2021 | $19,134,000 | +30.7% | 563,100 | +40.8% | 0.08% | +21.9% |
| Q2 2021 | $14,644,000 | -18.4% | 400,000 | 0.0% | 0.06% | -42.3% |
| Q1 2021 | $17,936,000 | -10.2% | 400,000 | +14.3% | 0.11% | -8.3% |
| Q4 2020 | $19,975,000 | – | 350,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,209,571 | $19,824,869 | 14.35% |
| Redmile Group, LLC | 3,593,317 | $58,894,466 | 2.41% |
| BRAIDWELL LP | 3,271,513 | $53,620,098 | 1.80% |
| Parkman Healthcare Partners LLC | 344,920 | $5,653,239 | 1.50% |
| ARMISTICE CAPITAL, LLC | 5,172,000 | $84,769,080 | 1.48% |
| Ikarian Capital, LLC | 367,119 | $6,017,081 | 1.45% |
| Sunesis Advisors, LLC | 96,299 | $1,578,341 | 1.01% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,349,228 | $38,503,847 | 0.80% |
| Hillsdale Investment Management Inc. | 328,200 | $5,379,198 | 0.46% |
| Avidity Partners Management LP | 1,126,000 | $18,455,140 | 0.40% |